Gregory Ehrlich1, Thomas Kirschning2, Holger Wenz3, Aldemar Andres Hegewald4, Eva Neumaier-Probst3, Marcel Seiz-Rosenhagen5. 1. Department of Neurosurgery, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany gregy.ehrlich@gmx.de gregory.ehrlich@umm.de. 2. Department of Anaesthesiology and Surgical Intensive Care Medicine, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany. 3. Department of Neuroradiology, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany. 4. Department of Neurosurgery, HELIOS Ostsee Hospital Damp, Ostseebad Damp, Germany. 5. Department of Neurosurgery, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany.
Abstract
BACKGROUND: Oral nimodipine is administered to improve clinical outcome in patients with aneurysmal subarachnoid hemorrhage (aSAH). In this study, clinical outcome in patients with and without oral nimodipine administration was assessed. MATERIALS AND METHODS: A total of 105 patients did not receive oral nimodipine but did receive intra-arterial nimodipine in the occurrence of hemodynamically relevant vasospasm after aSAH, whereas 74 patients received applications of both. Demographic/radiological details and clinical presentation were abstracted from the case records. RESULTS: Patient baseline characteristics were comparable, a predominance of endovascular coiling was shown in cohort 2 (p=0.0135). Severity of initial aSAH and clinical status at admission (Hunt and Hess) was significantly higher in those receiving oral nimodipine. Incidence of angiographic vasospasm was significantly higher in patients not treated with oral nimodipine (p=0.0305); a significantly better outcome measured by the National Institute of Health Stroke Scale (p=0.0213), was noted in those receiving oral nimodipine. CONCLUSION: Oral nimodipine administration improved clinical outcome of patients after aSAH and should be administered routinely for such patients. Copyright
BACKGROUND: Oral nimodipine is administered to improve clinical outcome in patients with aneurysmal subarachnoid hemorrhage (aSAH). In this study, clinical outcome in patients with and without oral nimodipine administration was assessed. MATERIALS AND METHODS: A total of 105 patients did not receive oral nimodipine but did receive intra-arterial nimodipine in the occurrence of hemodynamically relevant vasospasm after aSAH, whereas 74 patients received applications of both. Demographic/radiological details and clinical presentation were abstracted from the case records. RESULTS:Patient baseline characteristics were comparable, a predominance of endovascular coiling was shown in cohort 2 (p=0.0135). Severity of initial aSAH and clinical status at admission (Hunt and Hess) was significantly higher in those receiving oral nimodipine. Incidence of angiographic vasospasm was significantly higher in patients not treated with oral nimodipine (p=0.0305); a significantly better outcome measured by the National Institute of Health Stroke Scale (p=0.0213), was noted in those receiving oral nimodipine. CONCLUSION: Oral nimodipine administration improved clinical outcome of patients after aSAH and should be administered routinely for such patients. Copyright
Authors: Richard S Veyna; Donald Seyfried; Don G Burke; Chris Zimmerman; Mark Mlynarek; Victoria Nichols; Anna Marrocco; Ajith J Thomas; Panayiotis D Mitsias; Ghiaus M Malik Journal: J Neurosurg Date: 2002-03 Impact factor: 5.115
Authors: G S Allen; H S Ahn; T J Preziosi; R Battye; S C Boone; S C Boone; S N Chou; D L Kelly; B K Weir; R A Crabbe; P J Lavik; S B Rosenbloom; F C Dorsey; C R Ingram; D E Mellits; L A Bertsch; D P Boisvert; M B Hundley; R K Johnson; J A Strom; C R Transou Journal: N Engl J Med Date: 1983-03-17 Impact factor: 91.245
Authors: S M Dorhout Mees; G J E Rinkel; V L Feigin; A Algra; W M van den Bergh; M Vermeulen; J van Gijn Journal: Cochrane Database Syst Rev Date: 2007-07-18
Authors: Johannes Walter; Martin Grutza; Markus Möhlenbruch; Dominik Vollherbst; Lidia Vogt; Andreas Unterberg; Klaus Zweckberger Journal: J Clin Med Date: 2022-04-05 Impact factor: 4.241